• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

The Current Mature Market for Hormonal Contraceptives and Infertility Drugs

Posted on: Wednesday, 8 March 2006, 12:00 CST

Research and Markets (http://www.researchandmarkets.com/reports/c30827) has announced the addition of Spectra Intelligence Report "The Global Market for Hormonal Contraceptives and Infertility Drugs, 2005-2012" to their offering.

Drugs in reproductive medicine are evolving into highly sophisticated products with multifunctional pharmacological properties and clinical utilities. Novel contraceptive formulations with low side-effect profiles are providing women with flexible birthcontrol and menstrual management options whilst also offering secondary indications to treat coexisting endocrinological and gynaecological disorders. Furthermore, the increasing global prevalence of infertility is driving R&D to offer novel drug solutions to improve or restore male- and female-factor infertility, optimize fertilization and embryo implantation, and reduce miscarriage.

Recent advances in administering and formulating hormone-based drugs is enabling a revolution in contraception and infertility treatments. Over the next decade, the market for hormonal contraceptives and infertility drugs is predicted to expand considerably through innovation, new and expanding markets, and high value prospects that importantly offer novel solutions to unmet needs and demands of patients who wish to modulate or enhance fertility. The current mature market for hormonal contraceptives and infertility drugs is estimated at US$7.1 billion but is forecast to increase 40% to US$9.9 billion by 2012.

This report provides a detailed analysis of the global market for hormonal contraceptives and infertility drugs highlighting strategies for product extension and reformulation, sales forecasts to 2012 for leading products, and impact of late-stage pipeline drugs on the market. Therapy area forecasting and illustrative market data and analysis is also presented to offer insights into sector performance, which may enable the reader to make key assumptions about future markets and prospects.

Report Highlights and Key Findings

-- The current market for the hormonal contraceptives and infertility drugs is valued at US$7.1 billion, which is forecast to increase 40% to US$9.9 billion by 2012

-- Critical analysis of marketed hormonal contraceptives, reformulations, and infertility drugs

-- Analysis of over 10 key marketed products and inclusion of 38 R&D candidates identified in preclinical to clinical stages of development

-- Sales estimates (US$) to 2012 for leading products

-- Strategic insights for life-cycle optimization and product development

-- Commercial evaluation of leading reproductive health pharmacotherapies

-- Trend analysis of industry events and activities over past 2 years

-- Detailed R&D themes and clusters by therapy area

-- Data generation on sector and market values between 2004 and 2012 and therapy area forecasts by 2020 (US$)

-- High revenue-yielding prospects identified with projected sales estimations

-- R&D pipeline positioning for novel candidates

-- Market insights for product development and drug promotion

What Can I Learn From This Report?

-- Which contraceptives and infertility drugs are the current and potential future market leaders?

-- Insights into the extent of reformulations for hormonal contraceptive products

-- What impact new drug approvals will have on the reproductive medicine drug market?

-- Which premarket drugs are identified as high-value products?

-- Which companies are developing hormonal contraceptives and infertility drugs?

-- Sales predictions to 2012 for leading contraceptives and infertility drugs

-- How will newcomers affect the product positioning of market leaders

-- What are niche market opportunities in reproductive medicine?

-- What the future outlook holds for hormonal contraceptives and infertility pharmacotherapy?

-- How companies are expanding the global reproductive medicine market through sophisticated reformulations and secondary indications for endocrinological and gynaecological disorders

-- Which molecules and compounds are main R&D clusters in reproductive medicine?

-- Which of the pipeline candidates are identified as top prospects over the next decade and to 2020?

Plus Many Other Insights, Observations, Assumptions, and Predictions to be Garnered...

Companies Mentioned:

-- Acrux

-- Agile Therapeutics

-- Akzo Nobel

-- Antares Pharma

-- Ardana

-- Astrazeneca

-- Barr Laboratories

-- Berlex

-- Enhance Biotech

-- Ferring

-- Gropep

-- Johnson & Johnson

-- Laboratoire Theramex

-- Ligand

-- Organon

-- Ortho-Mcneil Pharmaceuticals

-- Pfizer

-- Polydex Pharma

-- Sanofi-Aventis

-- Schering Ag

-- Serono

-- Solvay

-- Vitro Diagnostics

-- Wyeth

For more information visit http://www.researchandmarkets.com/reports/c30827

Source: Business Wire

More News in this Category